research Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
A cancer patient's hair became permanently curly after treatment with nivolumab.
Search
for
Sort by
Research
300-330 / 1000+ resultsresearch Barraquer–Simons syndrome with benign infundibulocystic proliferation
Pimozide treatment resolved cysts and partially restored cheek fat in a man with Barraquer–Simons syndrome.
research 131 Mutational landscape of extramammary Paget disease
The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
research Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
research Effects of adenosine triphosphate on vandetanib induced skin damage in rats
ATP helps prevent skin damage from vandetanib by reducing stress.
research Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Bioassay-guided isolation of two antiproliferative metabolites from Pterocarpus indicus Willd. against TGF-β-induced prostate stromal cells (WPMY-1) proliferation via PI3K/AKT signaling pathway
Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.
research Characterization of aberrant mTOR signaling pathway in U87MG glioblastoma cell line by quantitative phosphoproteomics
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
research Hand-Foot and Stump Syndrome to Sorafenib
Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
research ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ
Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.
research Prostaglandin E2 prevents radiotherapy-induced alopecia by attenuating transit amplifying cell apoptosis through promoting G1 arrest
Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
research Upadacitinib for Alopecia: Current Evidence and Clinical Insights
Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
research Biopharmaceutical research on the choice of a non-steroidal anti-inflammatory agent in the development of combination gel for mastopathy therapy
Indometacin was chosen for a gel to help treat mastopathy and prevent breast cancer.
research Mitoxantrone, Etoposide and Prednisolone—a Novel Combination in The Treatment of Relapsed and Refractory Lymphoma
The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
research Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis
Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
research Nanoliposomal Co-Delivery of AR-PROTAC and NFKBIZ siRNA for Synergistic Therapy of Androgenetic Alopecia
A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
research Comparison of the pharmacoeconomic profiles of treatment regimens for field pattern actinic keratoses
Some blood pressure medications are linked to a higher risk of skin cancer.
research Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
Nail changes from immunotherapy can be managed without stopping cancer treatment.
research Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Peroxisome proliferator-activated receptor-γ signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial–mesenchymal transition
Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.
research Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer
A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.